Discretionary denials impact US life sciences IP strategies, but not as much as might be thought
SCOTUS refuses to consider NHK-Fintiv legal challenges, with significant implications for PTAB actions
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.